GW Henssler & Associates Ltd. Buys Shares of 11,614 UiPath Inc. (NYSE:PATH)

GW Henssler & Associates Ltd. purchased a new position in UiPath Inc. (NYSE:PATH) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,614 shares of the healthcare company’s stock, valued at approximately $149,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC lifted its position in UiPath by 15.3% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 30,479 shares of the healthcare company’s stock valued at $691,000 after acquiring an additional 4,039 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in shares of UiPath by 79.7% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 29,578 shares of the healthcare company’s stock worth $671,000 after purchasing an additional 13,114 shares in the last quarter. Diversified Trust Co purchased a new position in UiPath during the 1st quarter worth $553,000. Allspring Global Investments Holdings LLC increased its position in UiPath by 819.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 19,209 shares of the healthcare company’s stock valued at $435,000 after buying an additional 17,120 shares in the last quarter. Finally, Kovack Advisors Inc. purchased a new stake in UiPath in the first quarter valued at about $220,000. 62.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Royal Bank of Canada restated a “sector perform” rating and set a $16.00 price objective on shares of UiPath in a report on Friday, September 6th. JPMorgan Chase & Co. decreased their price target on shares of UiPath from $19.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, October 23rd. BMO Capital Markets boosted their price objective on shares of UiPath from $14.00 to $15.00 and gave the company a “market perform” rating in a report on Friday, September 6th. Needham & Company LLC restated a “hold” rating on shares of UiPath in a research note on Wednesday, October 23rd. Finally, Bank of America lifted their price target on UiPath from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Friday, September 6th. Sixteen investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $17.47.

Insider Transactions at UiPath

In related news, CFO Ashim Gupta sold 47,671 shares of UiPath stock in a transaction on Friday, September 13th. The shares were sold at an average price of $12.07, for a total value of $575,388.97. Following the sale, the chief financial officer now owns 849,917 shares of the company’s stock, valued at approximately $10,258,498.19. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 22.37% of the company’s stock.

UiPath Price Performance

PATH opened at $12.70 on Wednesday. The firm has a fifty day moving average price of $12.52 and a 200 day moving average price of $13.93. UiPath Inc. has a 1 year low of $10.37 and a 1 year high of $27.87. The stock has a market cap of $6.98 billion, a P/E ratio of -63.50 and a beta of 0.88.

UiPath (NYSE:PATH) last posted its earnings results on Thursday, September 5th. The healthcare company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. The firm had revenue of $316.00 million for the quarter, compared to analysts’ expectations of $303.69 million. UiPath had a negative return on equity of 3.98% and a negative net margin of 8.13%. The company’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period last year, the firm earned ($0.09) EPS. Equities analysts expect that UiPath Inc. will post -0.23 EPS for the current year.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.